Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
05 juin 2023 16h01 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
01 juin 2023 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
08 mai 2023 16h01 HE
|
Ocular Therapeutix, Inc.
12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented in June at the Clinical Trials at the Summit...
Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
08 mai 2023 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
28 avr. 2023 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
24 avr. 2023 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
14 avr. 2023 16h01 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
06 mars 2023 16h01 HE
|
Ocular Therapeutix, Inc.
Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and...
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
28 févr. 2023 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
21 févr. 2023 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...